Radioimmunotherapy in relapsed/refractory mantle cell lymphoma patients: final results of a European MCL Network Phase II Trial

Leukemia. 2016 Apr;30(4):984-7. doi: 10.1038/leu.2015.215. Epub 2015 Aug 5.
No abstract available

Publication types

  • Clinical Trial, Phase II
  • Letter
  • Multicenter Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Aged, 80 and over
  • Antibodies, Monoclonal / therapeutic use*
  • Drug Resistance, Neoplasm*
  • Europe
  • Female
  • Follow-Up Studies
  • Humans
  • Lymphoma, Mantle-Cell / immunology
  • Lymphoma, Mantle-Cell / mortality
  • Lymphoma, Mantle-Cell / pathology
  • Lymphoma, Mantle-Cell / therapy*
  • Male
  • Middle Aged
  • Neoplasm Recurrence, Local / immunology
  • Neoplasm Recurrence, Local / mortality
  • Neoplasm Recurrence, Local / pathology
  • Neoplasm Recurrence, Local / therapy*
  • Neoplasm Staging
  • Prognosis
  • Prospective Studies
  • Radioimmunotherapy*
  • Survival Rate
  • Yttrium Radioisotopes / therapeutic use*

Substances

  • Antibodies, Monoclonal
  • Yttrium Radioisotopes
  • ibritumomab tiuxetan